Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. - Wikidata - awgldk - TriplyDB

Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.

Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.

http://www.wikidata.org/entity/Q33270030

about

Interventions for the management of esophageal candidiasis in immunocompromised patients Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children The 2015 Clinical Guidelines for the Treatment and Prevention of Opportunistic Infections in HIV-Infected Koreans: Guidelines for Opportunistic Infections Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents Posaconazole: an oral triazole with an extended spectrum of activity Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of Amer Oropharyngeal candidiasis in the era of antiretroviral therapy Novel high-throughput screen against Candida albicans identifies antifungal potentiators and agents effective against biofilms.Current and developing therapeutic agents in the treatment of Chagas disease Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection Anti-Candida activity of Quercus infectoria gall extracts against Candida species Management of oropharyngeal candidiasis with localized oral miconazole therapy: efficacy, safety, and patient acceptability Antimicrobial therapy for the treatment of opportunistic infections in HIV/AIDS patients: a critical appraisal.Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.Role of posaconazole in the management of oropharyngeal and esophageal candidiasis Clinical pharmacology of antifungal agents in pediatric patients.Potentiation of azole antifungals by 2-adamantanamine Posaconazole in the management of refractory invasive fungal infections.Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066)New and investigational triazole agents for the treatment of invasive fungal infections.Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.Pharmacologic and clinical evaluation of posaconazole.Treatment strategies for oropharyngeal candidiasis.Candida tropicalis in human disease.Use of posaconazole in the treatment of invasive fungal infections.Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections.Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy.Posaconazole: when and how? The clinician's view.Safety of posaconazole.Urban legends series: oral manifestations of HIV infection.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole.Evaluation and Management of Infectious Esophagitis in Immunocompromised and Immunocompetent Individuals.Future therapies targeted towards eliminating Candida biofilms and associated infections.Oral fungi in HIV: challenges in antifungal therapies.Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole.Posaconazole for the management of mucosal candidiasis.

P2860

Q24188301-BA3EA810-531A-48FC-B985-64BB76E866AD Q24236693-E1A032EE-0D29-4EDC-871A-04EC121A0007 Q26751038-C954BECB-8158-4329-A885-3DD24BA0CBA6 Q26863344-6D4B4E54-47D2-4125-8DE9-53C2786F4E03 Q28291282-C07C3660-8E14-4D0E-B147-1B01552BF217 Q33650105-055493A0-6336-41F7-A6B9-00789F244FF7 Q33746435-98D10B99-95D8-4546-ACDE-E34068612021 Q33843060-BF82A6E1-80E0-478F-BF47-7D0D3094D55C Q34170132-E66944DC-D700-4542-8B06-BE81E608A522 Q34212799-182CD4ED-2BCF-4EA3-8A63-C4CEAC717DDE Q34505582-D7156636-3A4B-4584-8D66-2D01984228A1 Q34633796-B82AB244-3235-4C39-89D6-918DF211A9C8 Q35098733-D2032776-4152-4FEB-9E43-3EBAE87839D1 Q35147193-EC655B2F-70F2-470F-B33A-26005FB910A5 Q35557331-1CE2385A-BF75-40D4-9189-891D7E506781 Q36424973-09F8C706-BADD-427A-A17E-BD517328E546 Q36642964-CEDED8F6-5235-48C3-ACE7-5E762B2EAF18 Q36968140-810302AB-656F-4262-9A15-26E8D666F894 Q37036494-85BA0A07-9476-411A-9A74-DF086F0A57FF Q37052755-59A29187-CC27-46CD-A2FB-46C1662AA5C6 Q37055215-94993799-AB27-479A-8838-9EBE613F6C89 Q37180338-9CFF9D00-8EB4-4D39-A364-61A72CEE8261 Q37364295-571F6D95-A15D-4094-87A2-AB7E8F0E5DE2 Q37404840-13242805-0AF3-4B70-807A-C4E26439FBDF Q37445943-52AB3FE5-E747-49A2-A118-153E0D39F2FC Q37510887-625D24DE-5559-4CA8-A8E2-7B9112A0D44A Q37794979-819C5A14-32A4-4C13-8B4A-FEA851A1FA1A Q37810083-86B9CA3F-C489-475E-A26F-E4186C726875 Q37813420-4CF39169-2FE2-4205-96C1-7443BA2EE9F8 Q37889382-A23E0007-D772-4530-B748-8A570AA1AED5 Q37901534-60DFCDC6-7248-4A14-914C-9C70FCDC96FF Q38077591-415E5C8F-6DAE-4321-A9C3-D6D550C2C6EC Q38091715-22A8EAD9-43A9-4D86-B987-6F8287BD38CF Q38284468-0195FF6E-9F72-4DB6-BAB1-F943FD7CE671 Q38341595-4A7917DB-40B9-4191-A79A-FA7072F9CED9 Q38723613-5A6F028D-BA95-4AAC-81A0-145198ED67F7 Q38786061-AAB5D182-0045-4904-BC34-9162EC34CF48 Q38816198-FFF15611-E650-42A7-AC72-21F9DB67DAD6 Q38899363-2B8A6232-395A-4213-B142-BF38996BE6BC Q40188971-390E11E1-EC76-4F85-BEAB-3F37F7161501

P2860

Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.

http://www.wikidata.org/entity/Q33270030

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

name

Posaconazole for the treatment ...... n subjects with HIV infection.

@ast

Posaconazole for the treatment ...... n subjects with HIV infection.

@en

Posaconazole for the treatment ...... n subjects with HIV infection.

@nl

type

label

Posaconazole for the treatment ...... n subjects with HIV infection.

@ast

Posaconazole for the treatment ...... n subjects with HIV infection.

@en

Posaconazole for the treatment ...... n subjects with HIV infection.

@nl

prefLabel

Posaconazole for the treatment ...... n subjects with HIV infection.

@ast

Posaconazole for the treatment ...... n subjects with HIV infection.

@en

Posaconazole for the treatment ...... n subjects with HIV infection.

@nl

P1433

Q33270030-F1C68342-C0BD-4883-A88D-04447BB544C1

P1476

Q33270030-5F07804E-E768-4B94-B124-016C3653D506

P2093

Q33270030-02ECC186-335F-4C55-B982-718F1CD17201

Q33270030-1D0F3D35-509D-4473-AF39-432D66CEECDA

Q33270030-313F9531-CDB2-4D15-9B90-8A17D8E5658A

Q33270030-3A3EE124-753C-4EB3-94AD-36F5B6873AD2

Q33270030-55A48B0A-DFB6-4C31-A6AA-BDE2CAA51B2D

Q33270030-695009A6-985E-42EA-8249-1E5AC31531A6

Q33270030-84C6F9D7-D387-4C9C-8324-82FAECD79901

Q33270030-89142352-A7CC-455C-AAB0-503FDB6FF286

Q33270030-9170E59D-D2A5-4CAF-90FC-759116D7C235

P304

Q33270030-A8C78455-CC88-4944-898F-ABF5C44ECB2F

P31

Q33270030-4CB23B62-5DF8-4C22-AAF8-513948E8506A

P356

Q33270030-97A08194-9873-46E8-A237-43CCDB4F9B8E

P407

Q33270030-6F75A11F-2CD5-4A78-A593-C364A2D8D97E

P433

Q33270030-434D5951-AF59-4C5F-B485-BFBC65D161BD

P478

Q33270030-58E86352-9ED9-4614-9850-60C271413807

P577

Q33270030-9646423D-C427-46FE-90A5-655DF24F8F07

P5875

Q33270030-25A532D9-2C3B-421D-AA82-DEC4089C1D3B

P698

Q33270030-BA0616A1-3F77-4BF0-8129-ADB86882BF43

P921

Q33270030-0EA3E8E1-43C5-4FBE-AE70-9F0DDFE7A03F

P356

P1433

Clinical Infectious Diseases

P1476

Posaconazole for the treatment ...... n subjects with HIV infection.

@en

P2093

Daniel J Skiest

http://www.w3.org/2001/XMLSchema#string

Douglas Ward

http://www.w3.org/2001/XMLSchema#string

Gregory M Anstead

http://www.w3.org/2001/XMLSchema#string

Jacques Reynes

http://www.w3.org/2001/XMLSchema#string

John R Graybill

http://www.w3.org/2001/XMLSchema#string

Jose A Vazquez

http://www.w3.org/2001/XMLSchema#string

Navdeep Boparai

http://www.w3.org/2001/XMLSchema#string

Randi Isaacs

http://www.w3.org/2001/XMLSchema#string

Roberta Hare

http://www.w3.org/2001/XMLSchema#string

P304

607-614

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/511039

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6560181

http://www.w3.org/2001/XMLSchema#string

P698

17243069

http://www.w3.org/2001/XMLSchema#string

P921